Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial.

Murtuza Bharmal,Jeremy Lambert,Jeffery S. Russell,Celeste Lebbe,Bartosz Chmielowski,Meliessa Hennessy,Alexia Marrel,Sandra P. D'Angelo

Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial.

2019

Murtuza Bharmal
Jeremy Lambert
Jeffery S. Russell
Celeste Lebbe
Bartosz Chmielowski
Meliessa Hennessy
Alexia Marrel
Sandra P. D'Angelo

90Background: MCC is a rare, aggressive skin cancer with a poor prognosis. Avelumab is the only anti–PD-L1 monoclonal antibody approved for treatment of mMCC. This qualitative research embedded in ...

Keywords:

Pathology
Oncology
Avelumab
Clinical trial
Medicine
Internal medicine
Merkel cell carcinoma
Skin cancer
qualitative interview
Monoclonal antibody
therapy naive
Qualitative research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations